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Abstract
Background: The results of two randomized phase 3 trials that investigated the use of laquinimod in patients with
relapsing-remitting multiple sclerosis were analyzed using a propensity score model.
Methods: The propensity score in each study was defined as the probability of an individual patient being
assigned to either the laquinimod or placebo study arm. The analysis included two main stages: (1) calculation of a
propensity score for each patient, given a broad set of baseline covariates that included second-degree interactions,
and (2) incorporation of the propensity score as another covariate into the predefined primary analysis model to
test the treatment effect of laquinimod (0.6 mg/d) vs placebo on the annualized relapse rate (ARR).
Results: The BRAVO study showed baseline imbalances for T2 volume and the proportion of patients with
gadolinium (Gd)-enhancing lesions, both parameters known to correlate with risk of relapse. Adjustment using the
propensity score as a categorical variable showed that the estimated difference in ARR between laquinimod and
placebo was 0.078, in favor of laquinimod.
In ALLEGRO, the baseline Gd-enhancing lesion mean score was higher for placebo vs laquinimod. When the
primary analysis model was adjusted for the propensity score as a categorical variable, the covariate adjusted
difference in mean ARR between laquinimod and placebo was 0.084, in favor of laquinimod.
Conclusions: Propensity scores addressing differences in baseline characteristics may be helpful to better
understand whether observed treatment effect differences in randomized controlled trials are accurate results or
result from inherent differences between patients with multiple sclerosis.
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Background
The propensity score has become increasingly popular
for adjusting uncontrolled treatment assignment in ob-
servational studies [1–7]. Absent randomization, base-
line characteristics may differ markedly between groups,
which may affect the validity of study findings [3–5]. In
recent years, propensity scores have been used to adjust
for covariate imbalance in nonrandomized studies [8–
10] and randomized controlled trials [11–13] in numer-
ous therapeutic areas, including multiple sclerosis (MS).
The purpose of the current study was to use a propen-
sity score model to reexamine the results of 2 random-
ized phase 3 trials that investigated the use of
laquinimod in patients with relapsing-remitting MS
(RRMS): Assessment of Oral Laquinimod in Preventing
Progression in Multiple Sclerosis (ALLEGRO) and
Benefit-Risk Assessment of Avonex and Laquinimod
(BRAVO). Although the study designs of ALLEGRO and
BRAVO were similar and were conducted in roughly the
same calendar years, the treatment effect of laquinimod
on the annualized relapse rate (ARR) and disability pro-
gression was found, based upon a predefined analysis
plan, to be more favorable in the former than in the lat-
ter trial [14, 15]. Subsequent investigations, including a
reexamination of the results of a prespecified sensitivity
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analysis and further post hoc sensitivity analyses, sug-
gested that there was imbalance in a fundamental base-
line magnetic resonance imaging (MRI) characteristic
known to impact clinical outcomes. We used a propen-
sity score model to reassess the study results and
strengthen the findings of previous analyses by establish-
ing more consistency via understanding of the
imbalances.
Methods
The results of the ALLEGRO and BRAVO trials have
been described elsewhere, as have the findings of the
prespecified and post hoc sensitivity analyses [14, 15].
The following summaries are provided as context for the
current propensity score analysis.
Main findings from ALLEGRO and BRAVO
ALLEGRO was a double-blind, international study in
1106 patients with RRMS who were randomly assigned
in a 1:1 ratio to receive either oral laquinimod 0.6 mg
once daily or oral placebo for 24 months [14]. Treat-
ment with laquinimod vs placebo was associated with a
reduction in the mean ± standard error (SE) ARR (0.30
± 0.02 for laquinimod vs 0.39 ± 0.03, for placebo, P =
0.002). Laquinimod was also associated with significant
reductions in the risk of 3-month confirmed disability
progression, the mean cumulative number of gadolinium
(Gd)-enhancing lesions at 12 and 24 months, and the
cumulative number of new or enlarging lesions on T2-
weighted images [14].
BRAVO was a placebo-controlled, international study
in 1331 patients with RRMS who were randomly
assigned with equal probability to receive oral laquini-
mod 0.6 mg once daily, matching oral placebo, or inter-
feron beta-1a (IFNβ-1a) (30 μg intramuscularly once
weekly) for 24 months [15]. Patients who received IFNβ-
1a were excluded from this analysis, which is simplified
with just two groups. Treatment with laquinimod vs pla-
cebo was associated with a nonsignificant reduction in
ARR (0.28 ± 0.03 for laquinimod vs 0.34 ± 0.03 for pla-
cebo; risk ratio [RR] 0.82; 95 % confidence interval [CI]
0.66–1.02; P = 0.075) [15]. Percent brain volume change
from baseline to month 24 was significantly reduced
with laquinimod vs placebo [15].
Findings from prespecified and post hoc analyses
The BRAVO prespecified sensitivity analysis revealed
that the baseline mean volume of T2 lesions was greater
for laquinimod (9.6 cm3) than for placebo (7.9 cm3, P =
0.009). Further, more patients in the laquinimod group
(40 %) had Gd-enhancing lesions at baseline, despite
randomization, than did those in the placebo group
(33 %, P = 0.055) [15]. Previous literature has shown that
the number of new, active T2 lesions can serve as a
predictor of rate of relapse both in individual-patient
analysis and as observed in the ratio between experi-
mental and control arms in studies [16, 17]. Similarly,
the proportion of patients with Gd-enhancing lesions
and T2 lesion volume at baseline was found to be a
strong predictor of the rate of relapse during the
BRAVO study (β linear estimates of 0.45 with P < 0.0001
for the categorical Gd-enhancing T1 lesions and 0.0112
with P = 0.0126 for the continuous T2 volume variables);
therefore, they were added as covariates to the statistical
model for the purpose of conducting several post hoc
analyses [15].
In one post hoc analysis of the BRAVO study that in-
cluded the two baseline MRI parameters as covariates,
the ARR for laquinimod vs placebo was reduced by 21 %
(P = 0.0264), and the risk of worsening of disability con-
firmed at 3 months for laquinimod vs placebo was re-
duced by 33.5 % (P = 0.044) [15]. In another post hoc
analysis of the BRAVO study, the observed relapse rate
in the placebo group at 24 months was found to be
lower (0.34 relapses/year) than expected (0.6 relapses/
year) based on a post hoc power calculation made for the
study design, and thus, had the study been conducted
with this knowledge, it would have had only 48 % statis-
tical power to detect a significant treatment of the ob-
served effect of laquinimod vs placebo on ARR [15].
Propensity score model
The results from BRAVO suggested that, although
randomization assigned treatments in an unbiased man-
ner, imbalances still occurred, and exploring these might
improve the understanding of the results. Thus, explor-
ation via propensity scores might be useful. The propen-
sity score was defined as the probability of an individual
patient being assigned to either of the study arms (laqui-
nimod or placebo) given a known set of covariates. If
balance is to be obtained in those covariates, it is ex-
pected that for treatment the propensity score would re-
volve around 0.5 (given 2 treatment groups). The
propensity to be allocated into each group was summa-
rized into 1 score, and that score was used as a covariate
with 1 degree of freedom (in the case of a continuous
covariate) in the primary analysis model; this method al-
lows for adjustment as compared with performing ana-
lysis of covariance, which may involve too many
covariates simultaneously.
The goal of using a propensity score was to obtain an
estimate of the probability of being assigned to 1 or an-
other of the treatment arms based on characteristics
within the trial, when the theoretical probability was
known to be 0.50 [3]. A major concern in the use of pro-
pensity score analyses is having unmeasured covariates
critical in the assignment of treatments. This is not the
concern here because we accept that randomization has
Cutter et al. BMC Neurology  (2016) 16:176 Page 2 of 7
balanced the unmeasured covariates and we are only
adjusting for known differences as explanations for dif-
ferences in results. However, the potential for unmeas-
ured confounding variables cannot be fully ruled out,
and it may represent a potential limitation of the study.
Independent variables included pretreatment covariates
that may have been associated with treatment imbalance,
as well as the reported number of relapses. Explanatory
variables included age, sex, country, weight at baseline,
time from first symptom, time from diagnosis, tobacco
use, indicator for the number of Gd-enhancing lesions at
baseline, log of the total number of exacerbations in the
last year, log of the total number of exacerbations in the
last 2 years, baseline Expanded Disability Status Scale
(EDSS) score, baseline Multiple Sclerosis Functional
Composite score, T2 lesion volume at baseline, T1 lesion
hypointense volume at baseline, and normalized brain
volume at baseline. All second-degree interactions with
the variables listed were also included in the model, with
the exception of interactions with country because of
the small number of patients from some countries.
Baseline covariates not included because of missing
values were as follows: EDSS score on date of onset of
last exacerbation prior to randomization, EDSS score on
date of diagnosis of MS, time from date of onset of last
exacerbation, time from stabilization of last exacerba-
tion, and previous exposure to glatiramer acetate; race
was also omitted because nearly all of the patients were
white.
The analysis included two main stages: (1) calculation
of a propensity score for each patient, given a broad set
of baseline covariates that also included second-degree
interactions, and then (2) incorporating the propensity
score as another covariate into the predefined primary
analysis model to test the treatment effect of laquinimod
(0.6 mg/d) vs placebo on ARR. For comparative pur-
poses of this approach, the latter stage used two adjust-
ments approaches: one included a continuous propensity
score as a covariate, and the other subclassified the
range of the continuous propensity scores into quintiles
and included the quintile as a categorical variable (with
5 levels and 4 degrees of freedom).
Statistical analyses
The logistic regression model estimated the probability
for each patient to be assigned to the laquinimod arm;
thus, as expected from the baseline imbalances, propen-
sity scores for patients in both BRAVO and ALLEGRO
who actually received laquinimod were lower than those
for patients who actually received placebo. To simplify
the presentation of results, quintiles were used as cat-
egorical variables in the current analysis [18]. Propensity
score quintiles were calculated by combining the range
of values in the laquinimod and placebo groups.
Results
BRAVO study
In total, 880 patients were included in the BRAVO pro-
pensity score analysis; of these, 431 (of 434) were in the
laquinimod arm and 449 (of 450) were in the placebo arm.
Four patients (3 from the laquinimod arm and 1 from the
placebo arm) had missing values in Gd-enhancing lesions
and were not included in the analysis.
Summary statistics of propensity scores by treatment
group are shown in Table 1.
The distribution of propensity scores by treatment
group is shown in Fig. 1. The shift in the distribution be-
tween the groups is consistent with the slight imbalances
seen in the baseline characteristics. As shown, the shift
of the propensity score distributions between placebo
and laquinimod suggests higher propensity (given the
set of covariates) to be allocated to placebo rather than
laquinimod, had the randomization been performed as a
function of the covariates included. Individual propensity
scores by quintile are shown in Table 2.
In the unadjusted primary analysis of the BRAVO
study, laquinimod reduced the risk of relapse by 18 % vs
placebo (RR = 0.82; 95 % CI 0.66–1.02; P = 0.075), and
the unadjusted mean ARR was 0.28 ± 0.03 for laquini-
mod versus 0.34 ± 0.03 for placebo, a difference of 0.06
[15]. The primary analysis model for the effect on ARR
adjusting for continuous propensity score revealed that
laquinimod reduced the risk of relapse by 23.1 % vs pla-
cebo (RR = 0.769; 95 % CI 0.610–0.969; P = 0.026). The
estimated mean ARR was 0.268 (95 % CI 0.222–0.324)
for laquinimod vs 0.349 (95 % CI 0.292–0.417) for
placebo, a difference of 0.081. Adjustment using the
propensity score as a categorical variable showed that
laquinimod similarly reduced the risk of relapse by
22.4 % vs placebo (RR = 0.776; 95 % CI 0.616–0.978;
P = 0.0315), and the estimated ARR was 0.267 (95 %
CI 0.221–0.323) in the laquinimod group and 0.345
(95 % CI 0.288–0.412) in the placebo group, a differ-
ence of 0.078.
Table 1 Distribution of propensity score by treatment group in
the BRAVO study
Treatment group




Upper quartile 0.701 0.529
Median 0.586 0.407
Lower quartile 0.440 0.267
Minimum 0.109 0.007
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ALLEGRO study
In total, 1096 patients were included in the ALLEGRO
propensity score analysis; of these, 543 (of 550) were in
the laquinimod arm and 553 (of 556) were in the
placebo arm. Ten patients (7 from the laquinimod arm
and 3 from the placebo arm) had missing values (that is,
brain volume, Gd-enhancing lesions, T2 volume, T1
hypointense volume, weight, body mass index) and were
not included in the analysis.
Summary statistics of propensity scores by treatment
group are shown in Table 3.
The distribution of propensity scores by treatment
group is shown in Fig. 2. As can be seen, the shift of the
propensity score distributions between placebo and
laquinimod suggests higher propensity (given the set of
covariates) to be allocated to placebo rather than laqui-
nimod. Propensity scores by quintile are shown in
Table 4.
In the unadjusted primary analysis of the ALLEGRO
study, laquinimod reduced the risk of relapse by 23 % vs
placebo (RR = 0.77; 95 % CI 0.65–0.91; P = 0.002), and
the unadjusted mean ARR was 0.30 ± 0.02 for laquini-
mod versus 0.39 ± 0.03 for placebo, a difference of 0.09
[14]. When the primary analysis model was adjusted for
the propensity score as a continuous covariate, laquini-
mod reduced the risk of relapse by 19.2 % vs placebo
(RR = 0.808; 95 % CI 0.675–0.967; P = 0.0201), and the
covariate adjusted mean ARR was 0.308 (95 % CI 0.265–
0.357) for laquinimod vs 0.381 (95 % CI 0.332–0.437) for
placebo, a difference of 0.073. When the primary analysis
model was adjusted for the propensity score as a categor-
ical variable, laquinimod reduced the risk of relapse by
21.7 % vs placebo (RR = 0.783; 95 % CI 0.655–0.936; P =
0.0073), and the covariate adjusted mean ARR was 0.303
(95 % CI 0.261–0.351) for laquinimod and 0.387 (95 % CI
0.337–0.444) for placebo, a difference of 0.084.
Discussion
When a randomized trial is analyzed, the pre-planned
analyses using intention-to-treat or modified intention-to-
treat remain the preferred approach and the first analysis
to be done. However, when parallel trials are conducted
and differences in results are observed, it is important to
understand whether the divergent results are caused by a
lack of consistency in the outcomes or whether the differ-
ences can be explained by the impact of covariates that
were measured. The results of the current post hoc sensi-
tivity analysis using propensity scores in the reanalysis of
data from the ALLEGRO and BRAVO studies demon-
strate that, although randomization guarantees unbiased
assignment, randomization does not guarantee equality.
Often the variations in covariates that exist are still the re-
sult of unbiased assignment but may lead to observed dif-
ferences in covariates that can, and do, have measurable
effects on trial outcomes. In this example, the original
Fig. 1 Double-blind intent-to-treat distribution of propensity scores by treatment group in the BRAVO study
Table 2 Subclasses of propensity score in the BRAVO study






Table 3 Distribution of propensity score by treatment group in
the ALLEGRO study
Treatment group




Upper quartile 0.647 0.547
Median 0.540 0.448
Lower quartile 0.445 0.339
Minimum 0.106 0.034
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preplanned analysis was most likely affected by imbalances
in important baseline characteristics, and the propensity-
adjusted analyses confirm that the estimate of the treat-
ment effect is quite similar.
The propensity score, which can capture potential im-
balances concealed in baseline covariates in a single
number, can be implemented to strengthen a covariate
sensitivity analysis without overfitting a model by using
too many covariates. Propensity scores may be included
in statistical analyses through matching, stratification, or
regression adjustment; however, these analyses are most
often included in a regression model as an explanatory
variable, which is tantamount to covariate adjustment,
but sparing the degrees of freedom [19].
The BRAVO study showed baseline imbalance with re-
gard to T2 volume and the proportion of patients with
Gd-enhancing lesions. Both parameters are known to be
correlated with the occurrence of relapses, thereby hav-
ing a potential impact on the observed treatment effect
of laquinimod on ARR. When both baseline MRI param-
eters were introduced into the BRAVO primary model,
they were found to be strong predictors of the relapse
rate during the double-blind treatment phase; a similar
correlation was found in the ALLEGRO study. Unlike in
BRAVO, the inclusion of the propensity score in ALLE-
GRO decreased the treatment effect. The linear estimate
of the relationship between propensity score and treat-
ment effect was negative in ALLEGRO and positive in
BRAVO (when the propensity is defined as the probabil-
ity to be assigned with laquinimod), which explains the
opposite influence on the treatment effect, while trends
in propensity as shown in Figs. 1 and 2 are similar.
Numerous examples of the use of propensity scores to
analyze data from randomized controlled trials (RCTs)
can be found in the literature, and one study is of par-
ticular interest regarding the current discussion.
Recently, two different research groups conducted post
hoc analyses of the Atrial Fibrillation Follow-up Investi-
gation of Rhythm Management (AFFIRM) trial to evalu-
ate the causal effects of digoxin treatment on mortality
in patients with recurrent persistent atrial fibrillation
who were randomized to rate-control or rhythm-control
strategies [13, 20]. Both research groups used AFFIRM
data, and both groups used propensity score analysis (al-
beit different approaches), but their findings differed
[13]. Researchers who used propensity score covariate
adjustment reported that digoxin was associated with an
increase in all-cause mortality, whereas researchers who
used propensity score matching reported that it was not
[21, 22]. Although the use of different propensity score
approaches could potentially account for the discrep-
ancy, other explanations, including differences in patient
selection and the classification of digoxin exposure, are
also possible [13].
RCTs are viewed as the “gold standard” in clinical trial
design because, in general, they generate standardized
data from patient subgroups whose selection has been
based on strict criteria [2]. Indeed, one perspective is
that if baseline randomization is performed accurately,
different outcomes among patient subgroups represent a
treatment effect [2, 23]. In the case of unexpected find-
ings from RCTs or the suspicion of covariate imbalance,
statistical reanalysis using propensity scores may be ap-
propriate to better align patient subgroups when asses-
sing significance of treatment.
Conclusions
The current propensity analysis demonstrates through
example that baseline imbalances in RCTs such as those
Fig. 2 Double-blind intent-to-treat distribution of propensity scores by treatment group in the ALLEGRO study
Table 4 Subclasses of propensity score in the ALLEGRO study
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that occurred in BRAVO, which were absent in ALLE-
GRO, can contribute to numerical differences in treat-
ment results. When adjusted and better aligned, the
results of BRAVO more closely resembled those of AL-
LEGRO. These results point out that randomized studies
that may seem slightly inconsistent may, in fact, be quite
similar, and propensity score analyses might enable iden-
tification of those studies that are consistent with each
other and those that are not. Specifically, in the MS
treatment paradigm of reduction of relapse rates, pro-
pensity scores using baseline MRI characteristics can
prove helpful to adjust for and better reflect observed
differences in treatment effect in RCTs.
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